40
Participants
Start Date
June 2, 2020
Primary Completion Date
June 4, 2021
Study Completion Date
June 4, 2021
Enoxaparin Prefilled Syringe [Lovenox]
Twice-daily low-dose enoxaparin thromboprophylaxis (starting dose, 0.5 m/gkg subcutaneously q12 hours, adjusted to achieve a 4 hour post-dose anti-factor Xa level of 0.20-0.49 anti-Xa U/mL)
Cohen Children's Medical Center, New Hyde Park
Children's Hospital Pittsburgh, Pittsburgh
Johns Hopkins Hospital and Children's Center, Baltimore
Children's Hospital of Atlanta, Atlanta
Johns Hopkins All Children's Hospital, St. Petersburg
Children's of Alabama, Birmingham
Akron Children's Hospital, Akron
Children's Hospital of Michigan, Detroit
Lurie Children's Hospital, Chicago
Rush University Medical Center, Chicago
Children's Hospital New Orleans, New Orleans
Children's Medical Center of Dallas, Dallas
Children's Hospital Los Angeles, Los Angeles
Rady Children's Hospital, San Diego
Hemostasis and Thrombosis Center UC Davis, Sacramento
Boston Children's Hospital, Boston
Johns Hopkins All Children's Hospital
OTHER